{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069811","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.461415+00:00","generated_at":"2026-05-21T16:39:05.279965+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Mereo BioPharma Q1 net loss $12.9M; setrusumab Phase 3 Orbit on track for mid-year readout","bullets":["Net loss widened to $12.9M (Q1 2024: $9.0M) on operating loss of $11.2M.","Cash and equivalents $62.5M at March 31, 2025, down from $69.8M at year-end; runway into 2027.","R&D expenses $3.9M, flat YoY; setrusumab costs increased $1.3M offset by alvelestat decrease.","Phase 3 Orbit study of setrusumab in OI on track for second interim mid-2025 or final Q4 2025.","Alvelestat granted EU orphan designation for alpha-1 antitrypsin deficiency lung disease."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069811","json":"https://secwatch.observer/filing/0000950170-25-069811.json","markdown":"https://secwatch.observer/filing/0000950170-25-069811.md","text":"https://secwatch.observer/filing/0000950170-25-069811.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000095017025069811/0000950170-25-069811-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000095017025069811/mreo-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:39:05.279965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}